Newly Listed Company Introduction Report (Issued by The Stock Research Center)

Chordia Therapeutics (190A TSE Growth)June 19, 2024

Developing small-molecule drugs with modern mechanisms of action, specializing inoncology
This report is an English translation of part of the report issued on June 18, 2024.
For inquiries concerning the report, please contract info@stock-r.org【190A Chordia Therapeutics Sector：Pharmaceutical】
Fiscal YearNet sales

YoY(mn yen)(%)

OperatingprofitYoY(mn yen)(%)

Ordinary
profitYoY(mn yen)(%)

ProfitYoY(mn yen)(%)

EPSBPSDPS(yen)(yen)(yen)Aug. 2022---1,844--1,776--1,779-

-39.8

-72.4

0.0

Aug. 2023

2,500-212-

225-

223-

4.0

79.3

0.0

-

--2,273--2,278--2,280-

-40.4

-

0.0

Aug. 2024f

Note: Non-consolidated basis.Figures for the fiscal year ending August 2024 is the company's forecasts.
It conducted 1:200 stock split on June 2, 2023.Per share indicies are adjusted retroactively.

Developing Small-Molecule Drugs with Modern Mechanisms of Action,
Specializing in Oncology
Chordia Therapeutics is a bio-venture company established by Takeda Pharmaceuticals
researchers through Takeda Pharmaceuticals’ Entrepreneurship Venture Program.
The company is engaged in the research and development of first-in-class small-moleculedrugs with modern mechanisms of action specifically for cancer treatment. First-in-classdrugs are defined as innovative drugs that are highly novel, useful and significantly alter
conventional treatment systems.

Promoting Research and Development of Anti-Cancer Drugs Targeting RNA
Deregulation Stress
The company's R&D targets RNA deregulation stress, a cancer hallmark identified inrecent years. RNA deregulation stress is a condition that occurs when the RNA production
process, responsible for protein production in the cell, is disrupted and aberrant RNA
accumulates, applying load on the cell. Compared with normal cells, cancer cells areoverloaded. The anti-cancer effect is achieved through a mechanism of action that
selectively causes cancer cells to die by further production and accumulation of aberrant
RNA.
Chordia Therapeutics is a research and development leader in anti-cancer drugs targeting
RNA deregulation stress, which are not yet commercially available as pharmaceuticalproducts.

Business Model and Earnings Structure
Chordia Therapeutics focuses on research work such as drug exploration, preclinical andclinical research, particularly in the discovery, evaluation, optimization and clinical testingof candidate compounds. The company outsources basic research, manufacturing of drug
substances and formulations, distribution and sales to external partners.

Newly Listed Company Introduction Report

1/2

The contents indicated in the report are based on information as of the date the report was created and are subject to change without prior notice. The Stock Research Center
makes no warranty or representation concerning the accuracy, reliability, completeness, adequacy and reliability of the information indicated in the report, and shall not assume
no responsibility or obligation whatsoever. The Stock Research Center assumes no responsibility for any direct or indirect loss, lost profit, damage or other results from investors
accessing and using the report or relying on the report concerning the distribution of the report. Final investment decisions shall be made by the investors themselves, and entire
responsibility for investments lies with investors that accessed the report. In addition, intellectual rights concerning the report belongs to The Stock Research Center and may
not be copied, reprinted, quoted, etc. without permission.

Newly Listed Company Introduction Report (Issued by The Stock Research Center)

Chordia Therapeutics (190A TSE Growth)June 19, 2024

Financial Statements

Statement of income

Fiscal Year

Aug. 2022(mn yen)Six months
to Feb.2024

Aug. 2023(%)(mn yen)(%)(mn yen)(%)

Operating revenue--

2,500

100.0--

Operating expense

1,844-

2,287

91.0809-

Operating profit-1,844-2128.5-809-

94-

25-

11-

Non-operating income
Non-operating expenses

27-

12-

3-

Ordinary profit-1,776-225

9.0-801-

Profit before income taxes-1,776-225

9.0-801-

Net profit-1,779-223

8.9-802-

Balance sheet

Fiscal Year

Aug. 2022(mn yen)Current assets
Cash and deposits
Accounts receivable-trade
Inventories

Aug. 2023(%)(mn yen)Feb.2024(%)(mn yen)

(%)

4,482

99.6

4,891

99.6

3,885

99.6

4,254

94.6

4,799

97.8

3,746

96.0

-

-----------

160.4

170.3

160.4Property, plant and equipment

80.2

40.1

30.1

Intangible assets

40.1

2

0.0

1

0.0

Investments and other assets

40.1

100.2

110.3

4,498

100.0

4,909

100.0

3,902

100.0

221

4.9

408

8.3

204

5.2

-

-----

Non-current assets

Total assets
Current liabilities
Accounts payable - tradeNon-current liabilities
Net assets
Owners' equity

Statement of cash flows

Fiscal Year

Cash flows from operating activities
Depreciation

-----

-

4,277

95.1

4,500

91.7

3,698

94.8

4,251

94.5

4,474

91.1

3,672

94.1

(mn yen)(mn yen)Six months
to Feb.2024(mn yen)-1,704543-1,052

Aug. 2022

Aug. 2023

362

Cash flows from investing activities-1400

Cash flows from financing activities

3,975

-----

Dividends paid
Net increase in cash and cash equivalents

2,256

544

-1,052

Cash and cash equivalents

4,254

4,799

3,746

Note:Non-consolidated
Source: Prepared by Stock Research Center based on the notifiable prospectus.

Newly Listed Company Introduction Report

2/2

The contents indicated in the report are based on information as of the date the report was created and are subject to change without prior notice. The Stock Research Center
makes no warranty or representation concerning the accuracy, reliability, completeness, adequacy and reliability of the information indicated in the report, and shall not assume
no responsibility or obligation whatsoever. The Stock Research Center assumes no responsibility for any direct or indirect loss, lost profit, damage or other results from investors
accessing and using the report or relying on the report concerning the distribution of the report. Final investment decisions shall be made by the investors themselves, and entire
responsibility for investments lies with investors that accessed the report. In addition, intellectual rights concerning the report belongs to The Stock Research Center and may
not be copied, reprinted, quoted, etc. without permission.

About Stock Research Center
Stock Research Center is engaged in the preparation of analyst reports, mainly on companies that are not sufficiently
covered by analysts, based on a neutral perspective, and broadly disclose the reports to the public with an aim torevitalize the stock market.
Note: Reports prepared by Stock Research Center are created in reference to the Ministry of Economy, Trade andIndustry’s Guidance for Integrated Corporate Disclosure and Company-Investor Dialogues for Collaborative Value
Creation.

Discretionally select companies tocover, interview them and prepare
reports
Listed Companies

TSE, Securities Companies, Audit Companies, etc.

Support

Stock Research Center

Provide reports through websites,
smartphone apps, etc. (free of chargein principle)
Investors, Media, etc.

No cost burden on listed companies■Supporting Members
Tokyo Stock Exchange, Inc.
SMBC Nikko Securities Inc.
Nomura Securities Co., Ltd.
Mizuho Securities Co., Ltd.
KPMG AZSA LLC
ICMG Co., Ltd.
Deloitte Touche Tohmatsu LLC
SBI SECURITIES Co., Ltd.
PricewaterhouseCoopers Japan LLC
Ichiyoshi Securities Co., Ltd.
GYOSEI & CO.
Avantia G.P.
PRONEXUS INC.
Japan Securities Dealers Association
The Securities Analysts Association of Japan

Daiwa Securities Co. Ltd.
Ernst & Young ShinNihon LLC
Grant Thornton Taiyo LLCBDO Sanyu
A&A Partners
TAKARA PRINTING CO., LTD.

■Endorsement
Nagoya Stock Exchange, Inc.
Japan Venture Capital Association

Sapporo Securities Exchange
Japan Investor Relations Association

Certification by Analysts
Analysts indicated in the reports certify that the content indicated in the report precisely reflects the personal opinions of the analysts
on all securities and issuer companies discussed in the report. In addition, it is ensured that the opinions directly or indirectly indicatedin the report will have no influence on the analyst’s compensation in the past, present, and future upon writing the report.

Disclaimer∙ The report is prepared by stock analysts affiliated with the Stock Research Center for the purpose of disclosure to a wide range ofinvestors as reference information and not to recommend or solicit to buy or to sell any particular securities or financial instrument.
∙ The content and indication of the report is based on disclosed information available publicly and is prepared by adding necessary
supplementary information gained through interviews by analysts. The writer of the report is, without exception, prohibited to use
insider information, or to acquire such information. The information included in the report is believed to be precise and reliable, but
its preciseness is not verified objectively. In addition, the report is not intended to comprehensively include all information requiredby investors.
∙ The information included in the report may become outdated due to changes in the financial market, economic environment, etc.
There are risks that the prices of stocks featured directly or indirectly in the report will fall below the par value due to fluctuations instock prices, changes in management/financial conditions of the issuers, fluctuations in exchange rates or interest rates, etc. Past
performance does not imply or guarantee future performance.
∙ The opinions indicated in the report are subject to change without notice and the Stock Research Center has no obligation to update
the information or opinions included in the report.
∙ The Stock Research Center does not bear any responsibility for any results, including direct losses, indirect losses, losses of profit
and damages, suffered by investors due to using the report or relying on the report. Final investment decisions shall be made byinvestors themselves and the sole responsibility concerning the investment lies with the investors that viewed the report.
∙ The copyright of the report belongs to the Stock Research Center and it may not be copied, reproduced, quoted, etc. in any form
without prior consent.